Bank of America Downgrades Nektar Therapeutics to Underperform

Loading...
Loading...
Bank of America has downgraded Nektar Therapeutics
NKTR
from Neutral to Underperform and maintains its $6 price objective.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: DowngradesPrice TargetPre-Market OutlookAnalyst RatingsBank of America
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...